Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Margetuximab in HER2-positive metastatic breast cancer
NCT05227131Phase 2Withdrawn
- Sponsor
- MEDSIR
- Start
- May 2022
- Primary completion
- Oct 2024
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
01
Overview
A Phase 2 trial of margetuximab in breast cancer, HER2-positive breast cancer, sponsored by MEDSIR. Planned start May 2022; status: withdrawn.
02
Drugs
margetuximab
03
Conditions
breast cancerHER2-positive breast cancer
Beyond the preview
Go deeper on NCT05227131.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05227131.